Stocks:
5,472
ETFs:
2,400
Exchanges:
11
Market Cap:
$58.55T
24h Vol:
$9.62B
Dominance:
MSFT:5.17%
Stocklytics Platform
BETA
Instrument logo  LLY

Eli Lilly & Co

LLY
72 / 100
High Growth
S&P500
$771.91arrow_drop_up0.30%$2.38
Key Stats
Open$771.29
Prev. Close$769.53
EPS5.77
Dividend$4.52
Next Earnings DateJun 7, 2024
Dividend Yield %0.68%
Market Cap$733.45B
PE Ratio133.78
LOWHIGH
Day Range769.12
780.21
52 Week Range309.20
794.46
Ratios
P/B Ratio67.88
Revenue$32.07B
Operating M. %34.14%
Earnings$4.98B
Earnings Growth %-20.12%
EBITDA Margin %38.40%
ROE %48.44%
EPS5.77
Fundamentals
RPS$37.91
Gross Profit$25.23B
EBITDA$12.45B
Total Debt$26.46B
P/S Ratio21.4x
Enterprise to EBITDA87.94
Profit Margin15.36%
ROA11.88%
Debt/Equity Ratio2.44%
Payout Ratio74.21%
Industry average yield3.04%
Last Dividend pay dateMar 8, 2024
Dividend per share$4.52
Dividend yield forecast0.01%

Stock Analysis

Technicals

Summarizing what the indicators are suggesting.

Strong Buy
Buy
Neutral
Sell
Strong Sell
Analyst rating

An aggregate view of professional's ratings.

Strong Buy
Buy
Neutral
Sell
Strong Sell

Stock Performance

LLYarrow_drop_down-0.01%
US Healthcare Sectorarrow_drop_up0.66%
US Marketarrow_drop_up0.51%
LLY / Market
LLY lose to the US Market which returned 0.51% over the last twenty four hours.
LLY / Healthcare Sector
LLY lose to the US Healthcare sector which returned 0.66% over the last twenty four hours.

Eli Lilly & Co (LLY) Statistics

Founded in 1876, Eli Lilly & Co (LLY) is a global pharmaceutical company that is focused on discovering, developing, and delivering innovative medicines to improve the lives of people around the world. With a market capitalization of over $200 billion, Eli Lilly is a leader in the pharmaceutical industry. The company's stock performance has been impressive, consistently outperforming the broader sector. Over the past year, LLY stock has delivered a return of over 40%, compared to just 20% for the sector as a whole.

One of the key valuation metrics for Eli Lilly is its enterprise to EBITDA ratio, which measures the company's valuation relative to its earnings before interest, taxes, depreciation, and amortization. As of the latest financial report, Eli Lilly's enterprise to EBITDA ratio stands at 16. This indicates that the company's stock is trading at a relatively attractive valuation compared to its earnings potential.

add Eli Lilly & Co to watchlist

Keep an eye on Eli Lilly & Co

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
question_mark
How has Eli Lilly & Co (LLY) stock's performance compared to its sector and the market over the past year?

Over the past year, Eli Lilly & Co (LLY) has experienced a price change of 142.99%. Compared to the Healthcare sector, which saw a change of 35.20%, Eli Lilly & Co has underperformed compared to its sector, indicating its relative standing within the Healthcare sector. Against the broader market's change of 39.07%, it has fallen short of the market average. This comparison highlights Eli Lilly & Co's performance relative to both its sector and the overall market over the last year.

question_mark
What is the PE ratio of Eli Lilly & Co (LLY) stock?

The PE (Price to Earnings) ratio of Eli Lilly & Co (LLY) is currently 133.37. This metric is used to evaluate the valuation of a company's stock, comparing its current share price relative to its per-share earnings.

question_mark
What is the EPS of Eli Lilly & Co (LLY) stock?

The Earnings Per Share (EPS) for Eli Lilly & Co (LLY), calculated on a diluted basis, is $5.77. EPS is a key indicator of a company's profitability, showing the portion of a company's profit allocated to each outstanding share of common stock.

question_mark
What is the operating margin of Eli Lilly & Co (LLY) stock?

The operating margin for Eli Lilly & Co (LLY) is 34.14%. This metric represents the percentage of revenue that remains after paying for variable production costs, indicating the efficiency and profitability of the company's core business operations.

question_mark
What is the EBITDA of Eli Lilly & Co (LLY) stock?

The EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of Eli Lilly & Co (LLY) is $12.46B. EBITDA is a widely used earnings metric to assess a company's operational efficiency and profitability before the impact of non-operating decisions such as financing, accounting, and tax environments.

question_mark
How much debt does Eli Lilly & Co (LLY) have?

Eli Lilly & Co (LLY) has a total debt of $26.47B. The net debt, which accounts for cash and cash equivalents against the total debt, is $22.41B.

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Approach investments with caution like a driver who slows down on a curvy road.